Asterias Biotherapeutics (AST) Misses Q3 EPS by 7c

November 14, 2016 4:44 PM EST

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Asterias Biotherapeutics (NYSE: AST) reported Q3 EPS of ($0.24), $0.07 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $2.1 million versus the consensus estimate of $1.5 million.

As of September 30, 2016, the company's cash, cash equivalents and available-for-sale securities totaled $33.9 million, which management believes will be sufficient to fund operations through the third quarter of 2017.

For earnings history and earnings-related data on Asterias Biotherapeutics (AST) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Earnings

Related Entities

Earnings

Add Your Comment